Key result
In CKD patients on statins, targeting SBP <120 mm Hg reduced all-cause mortality compared to <140 mm Hg, an effect not seen without statins.
Why the study?
Optimal management of hypertension and statin therapy are key risk-modifying strategies in chronic kidney disease, but the modifying effect of statins on systolic blood pressure goals and mortality is unclear.
Does an intensive SBP goal < 120 mm Hg reduce all-cause and cardiovascular mortality compared to a standard SBP goal < 140 mm Hg in CKD patients, and is this effect modified by statin use?
RCT (n=2,646)
Randomized to an intensive SBP goal < 120 mm Hg or standard SBP goal <140 mm Hg
Does an intensive SBP goal < 120 mm Hg reduce all-cause and cardiovascular mortality compared to a standard SBP goal < 140 mm Hg in CKD patients, and is this effect modified by statin use?
Answers are grounded in this paper and cite their sources.
Intensive blood pressure lowering to <120 mm Hg provides significant mortality benefits in hypertensive patients with CKD specifically when combined with statin therapy.
BACKGROUND: Management of chronic kidney disease (CKD) patients includes efforts directed toward modifying traditional cardiovascular risk factors. Such efforts include optimal management of hypertension together with the initiation of statin therapy. METHODS: In this observational study, we determine the modifying effect of statins on the relationship of systolic blood pressure (SBP) goal with mortality and other outcomes in patients with CKD participating in a clinical trial. At baseline, 2,646 CKD patients (estimated glomerular filtration rate < 60 mL/min/1.73 m2) were randomized to an intensive SBP goal < 120 mm Hg or standard SBP goal <140 mm Hg. One thousand two hundred and seventy-three were not on statin, 1,354 were on a statin, and in 19 the use of statin was unknown. The 2 primary outcomes were all-cause mortality and cardiovascular disease (CVD) mortality. RESULTS: The relationships of SBP goal with all-cause mortality (interaction p = 0.009) and cardiovascular (CV) mortality (interaction p = 0.021) were modified by the use of statin after adjusting for age, gender, race, CVD history, smoking, aspirin use, and blood pressure at baseline. In the statin group, targeting SBP to < 120 mm Hg compared to SBP < 140 mm Hg significantly reduced the risk of all-cause mortality (adjusted hazard ratio [aHR] 0.44 [0.28-0.71]; event rates 1.16 vs. 2.5 per 100 patient-years) and CV mortality (aHR 0.29 [0.12-0.74]; event rates 0.28 vs. 0.92 per 100 patient-years) after a median follow-up of 3.26 years. In the non-statin group, the risk of all-cause mortality (aHR 1.07 [0.69-1.66]; event rates 2.01 vs. 1.94 per 100 patient-years) and CV mortality (aHR 1.42 [0.56-3.59]; event rates 0.52 vs. 0.41 per 100 patient-years) were not significantly different in both SBP goal arms. CONCLUSION: The combination of statin therapy and intensive SBP management leads to improved survival in hypertensive patients with CKD.
No takes yet. Share an insight, caveat, or question.
Rivera et al. (2019) conducted an RCT in Chronic kidney disease and hypertension (n=2,646). Intensive SBP goal vs. Standard SBP goal < 140 mm Hg was evaluated on All-cause mortality (in patients on statin therapy) (aHR 0.44, 95% CI 0.28-0.71). In CKD patients on statins, targeting SBP <120 mm Hg reduced all-cause mortality compared to <140 mm Hg, an effect not seen without statins.
Synapse has enriched 10 related papers. Consider them for comparative context: